Somerset Pharmaceuticals, Inc.

Cheryl D Blume

Anthony R DiSanto

Methods and pharmaceutical compositions for using desmethylselegiline. In particular, the present invention provides novel compositions and methods for using desmethylselegiline for selegiline-responsive diseases and conditions. Diseases and conditions responsive to selegiline include those produced by neuronal degeneration or neuronal trauma and those due to immune system dysfunction. Desmethylselegiline is the R-(&minus;) enantiomer of N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane. Claimed compositions include both the R-(&minus;) isomer and mixtures of the R-(&minus;) and S(&plus;) isomers. Pharmaceutically acceptable acid addition salts may also be used. Effective dosages are a daily dose of at least about 0.015 mg/kg of body weight.

Methods for treating multiple sclerosis employing desmethylselegiline

The application is directed to the treatment of one or more symptoms associated with drug withdrawal by administering desmethylselegiline.

Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms

Methods employing R(&minus;)-desmethylselegiline

The application is directed to the treatment of neoplastic diseases or conditions by administering R(&minus;) desmethylselegiline, S(&plus;) desmethylselegiline, or a combination of the two. Neoplastic diseases and conditions responsive to R(&minus;) desmethylselegiline and/or S(&plus;) desmethylselegiline include both malignant and benign neoplasms.

Growing community of inventors

Tampa, FL, United States of America

Cheryl D Blume